HK1077804A1 - (20S)-1Alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses - Google Patents

(20S)-1Alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses

Info

Publication number
HK1077804A1
HK1077804A1 HK05109794A HK05109794A HK1077804A1 HK 1077804 A1 HK1077804 A1 HK 1077804A1 HK 05109794 A HK05109794 A HK 05109794A HK 05109794 A HK05109794 A HK 05109794A HK 1077804 A1 HK1077804 A1 HK 1077804A1
Authority
HK
Hong Kong
Prior art keywords
skin
compound
bishomopregnacalciferol
methylene
hydroxy
Prior art date
Application number
HK05109794A
Other languages
English (en)
Inventor
Hector F Deluca
Lori A Plum
Margaret Clagett-Dame
James B Thoden
Hazel M Holden
Sumithra Gowlugari
Pawel Grzywacz
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/078,204 external-priority patent/US6627622B2/en
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of HK1077804A1 publication Critical patent/HK1077804A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
HK05109794A 2001-12-13 2005-11-03 (20S)-1Alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses HK1077804A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34113801P 2001-12-13 2001-12-13
US10/078,204 US6627622B2 (en) 2002-02-18 2002-02-18 (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
PCT/US2002/039715 WO2003051828A2 (fr) 2001-12-13 2002-12-12 (20s)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol et ses utilisations

Publications (1)

Publication Number Publication Date
HK1077804A1 true HK1077804A1 (en) 2006-02-24

Family

ID=26760229

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05109794A HK1077804A1 (en) 2001-12-13 2005-11-03 (20S)-1Alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses

Country Status (17)

Country Link
EP (1) EP1453798B1 (fr)
JP (1) JP4149928B2 (fr)
KR (1) KR100631457B1 (fr)
CN (1) CN1308303C (fr)
AT (1) ATE411283T1 (fr)
AU (1) AU2002359680B2 (fr)
CA (1) CA2468833C (fr)
CY (1) CY1108686T1 (fr)
DE (1) DE60229430D1 (fr)
DK (1) DK1453798T3 (fr)
ES (1) ES2315426T3 (fr)
HK (1) HK1077804A1 (fr)
MX (1) MXPA04005652A (fr)
NZ (1) NZ533424A (fr)
PT (1) PT1453798E (fr)
SI (1) SI1453798T1 (fr)
WO (1) WO2003051828A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7704980B2 (en) * 2003-10-08 2010-04-27 Wisconsin Alumni Research Foundation Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
US8404667B2 (en) * 2006-12-29 2013-03-26 Wisconsin Alumni Research Foundation Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog
MX2007006094A (es) * 2004-11-22 2007-07-11 Wisconsin Alumni Res Found 2-metilen-19,21-dinor-1a-hidroxi-bishomopregnacalciferol.
WO2006057913A2 (fr) 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2-methylene-19-nor-(20r)-1-$g(a)-hydroxy-bishomopregnacalciferol
NZ555281A (en) * 2004-11-22 2011-01-28 Wisconsin Alumni Res Found 2-methylene-19,26,27-trinor-(20s)-1alpha-alpha-hydroxyvitamin D3 and its uses
CA2605727A1 (fr) 2005-05-03 2006-11-09 Wisconsin Alumni Research Foundation Composes de 19,26,27-trinor-1.alpha.,25-dihydroxyvitamine d3
US7648972B2 (en) * 2006-04-06 2010-01-19 Wisconsin Alumni Research Foundation 2-methylene-1α-hydroxy-19,21-dinorvitamin D3 analogs and uses thereof
WO2007118198A2 (fr) * 2006-04-06 2007-10-18 Wisconsin Alumni Research Foundation ANALOGUES DE LA 2-MÉTHYLÈNE-1α,25-DIHYDROXY-19,21-DINOR-VITAMINE D3 ET LEURS UTILISATIONS
JP2009532457A (ja) * 2006-04-06 2009-09-10 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−１α−ヒドロキシ−１８，１９，２１−トリノルビタミンＤ３類縁体およびその使用
US20080171728A1 (en) * 2007-01-12 2008-07-17 Quatrx Pharmaceuticals Co. Efficient Process for Preparing Steroids and Vitamin D Derivatives With the Unnatural Configuration at C20 (20 Alpha-Methyl) from Pregnenolone
EP2262507A1 (fr) * 2008-03-06 2010-12-22 Wisconsin Alumni Research Foundation Procédés d augmentation de l épaisseur de l épiderme par l administration topique d un composé de vitamine d contenant du 19-nor
US8993547B2 (en) * 2011-06-14 2015-03-31 Wisconsin Alumni Research Foundation 3-desoxy-2-methylene-19-nor-vitamin D analogs and their uses
WO2013012644A1 (fr) * 2011-07-18 2013-01-24 Wisconsin Alumni I Research Foundation Analogues de 2-méthylène-20(21)-déshydro-19,24,25,26,27-pentanor-vitamine d
US8410080B1 (en) * 2011-10-21 2013-04-02 Wisconsin Alumni Research Foundation 2-methylene-vitamin D analogs and their uses
CA2851275C (fr) * 2011-10-21 2020-07-14 Wisconsin Alumni Research Foundation Analogues de 2-methylene-vitamine d et leurs utilisations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2185017B (en) * 1985-04-23 1989-11-29 Wisconsin Alumni Res Found Seco-sterol compounds effective in inducing the differentiation of malignant cells
JPH05238937A (ja) * 1992-03-09 1993-09-17 Wisconsin Alumni Res Found 細胞分化誘発薬剤
US5843928A (en) * 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
NZ524657A (en) * 2000-09-08 2004-12-24 Wisconsin Alumni Res Found 1 alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications

Also Published As

Publication number Publication date
EP1453798B1 (fr) 2008-10-15
DK1453798T3 (da) 2009-02-16
CN1308303C (zh) 2007-04-04
ES2315426T3 (es) 2009-04-01
CA2468833C (fr) 2009-09-08
ATE411283T1 (de) 2008-10-15
PT1453798E (pt) 2009-01-23
KR20040063949A (ko) 2004-07-14
WO2003051828A3 (fr) 2003-09-12
AU2002359680A1 (en) 2003-06-30
DE60229430D1 (de) 2008-11-27
CY1108686T1 (el) 2014-04-09
MXPA04005652A (es) 2005-03-23
NZ533424A (en) 2006-08-31
JP4149928B2 (ja) 2008-09-17
CA2468833A1 (fr) 2003-06-26
CN1620431A (zh) 2005-05-25
JP2005513066A (ja) 2005-05-12
WO2003051828A2 (fr) 2003-06-26
AU2002359680B2 (en) 2007-10-18
EP1453798A2 (fr) 2004-09-08
KR100631457B1 (ko) 2006-10-11
SI1453798T1 (sl) 2009-04-30

Similar Documents

Publication Publication Date Title
HK1077804A1 (en) (20S)-1Alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
HK1077508A1 (en) 1-Alpha-hydroxy-2-methylene-19-nor-pregnacal ciferol and its uses
IL154699A0 (en) 1alpha-HYDROXY-2-METHYLENE-19-NOR-HOMOPREGNACALCIFEROL AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
ATE415164T1 (de) (20s)-1alpha-hydroxy-2alpha-methyl und 2beta- methyl-19-nor vitamin d3 und ihre verwendung
WO2006057884A3 (fr) Analogues 2$g(a)-methyl et 2$g(b)-methyl de 19,26,27-trinor-(20s)-1$g(a)-hydroxyvitamine d3 et leurs utilisations
WO2006057899A3 (fr) 2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol et ses utilisations
WO2006057901A3 (fr) 2-methylene-19-nor-1?-hydroxy-17-ene-homopregnacalciferol et ses utilisations
WO2006057886A3 (fr) 2-methylene-19,26,27-trinor-(20s)-1?-alpha-hydroxyvitamine d3 et ses utilisationsits uses
ATE472528T1 (de) 2-methylen-18,19-dinor-1alfa-hydroxy- homopregnacalciferol und dessen verwendungen
MX2010007205A (es) Analogos de vitamina d, 2-metilen-20-metil-19, 24, 25, 26, 27-pentanor.
MX2009002944A (es) Analogos de 2-metilen-(20s,25s)-19,27-dinor-(22e)-vitamina d.
WO2006057902A3 (fr) 2alpha-methyl-19-nor-1alpha-hydroxy-homopregnacalciferol et ses utilisations
WO2009086439A3 (fr) Analogues 2-méthylène-(20s,25s)-19,26-dinor

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20191212